Surgical delays of less than 1 year in Mohs surgery associated with tumor growth in moderately- and poorly-differentiated squamous cell carcinomas but not lower-grade squamous cell carcinomas or basal cell carcinomas: A retrospective analysis - 09/12/21
, Vernon J. Forrester, MD a, Wendy M. Novicoff, PhD b, Darren J. Guffey, MD a, Mark A. Russell, MD aAbstract |
Background |
Evidence is controversial and limited concerning whether surgical delays are associated with tumor growth for cutaneous squamous cell carcinomas (SCCs) and basal cell carcinomas.
Objective |
Identify tumor subpopulations that may demonstrate an association between tumor growth and surgical delay.
Methods |
We retrospectively analyzed 299 SCCs and 802 basal cell carcinomas treated with Mohs surgery at a single institution. Time interval from biopsy to surgery represented surgical delay. Change in major diameter (ΔMD) from size at biopsy to postoperative defect represented tumor growth. Independent predictors of ΔMD were identified by multivariate analysis. Linear regression was then utilized to assess for whether the ΔMD from these independent predictors trended with surgical delay.
Results |
Surgical delays ranged from 0 to 331 days. Among SCCs, histologic subtype and prior treatment were identified as independent predictors of ΔMD. Significant associations between ΔMD and surgical delay were found for poorly- and moderately-differentiated SCCs, demonstrating growth rates of 0.28 cm and 0.24 cm per month of delay, respectively. The ΔMD for SCCs with prior treatment and basal cell carcinoma subgroups did not vary with surgical delay.
Limitations |
Retrospective design, single center.
Conclusion |
Surgical delays of less than a year were associated with tumor growth for higher-grade SCCs, with effect sizes bearing potential for clinical significance.
Le texte complet de cet article est disponible en PDF.Key words : basal cell carcinoma, growth rate, lesion size, nonmelanoma skin cancer, skin cancer, squamous cell carcinoma, surgical delay, tumor growth, tumor size
Abbreviations used : BCC, ΔMD, NMSC, SCC, SCCIS
Plan
| Funding sources: None. |
|
| IRB approval status: Reviewed and approved by University of Virginia IRB (approval #21705). |
Vol 86 - N° 1
P. 131-139 - janvier 2022 Retour au numéro
Article précédent
- A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results
- Nina Magnolo, Külli Kingo, Vivian Laquer, John Browning, Adam Reich, Jacek C. Szepietowski, Deborah Keefe, Rafal Mazur, Prayashi Ghelani, Pascal Forrer, LindaAnn Wraith, Manmath Patekar
- Hidradenitis suppurativa in pediatric patients
- Ellie Choi, Xue Ting Ooi, Nisha Suyien Chandran
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?